Published August 13, 2014 | Version v1
Journal article

Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment

  • 1. Institute of Advanced Technology, Kyoto Sangyo University, Kita-ku, Kyoto 603-8555 (Japan)
  • 2. Division of Engineering (Biotechnology), Graduate School of Engineering, Kyoto Sangyo University, Kita-ku, Kyoto 603-8555 (Japan)
  • 3. Department of Animal Medical Sciences, Faculty of Life Sciences, Kyoto Sangyo University, Kita-ku, Kyoto 603-8555 (Japan)
  • 4. Department of Molecular Biosciences, Faculty of Life Sciences, Kyoto Sangyo University, Kita-ku, Kyoto 603-8555 (Japan)

Description

During tumor progression, circulating monocytes and macrophages are actively recruited into tumors where they alter the tumor microenvironment to accelerate tumor progression. Macrophages shift their functional phenotypes in response to various microenvironmental signals generated from tumor and stromal cells. Based on their function, macrophages are divided broadly into two categories: classical M1 and alternative M2 macrophages. The M1 macrophage is involved in the inflammatory response, pathogen clearance, and antitumor immunity. In contrast, the M2 macrophage influences an anti-inflammatory response, wound healing, and pro-tumorigenic properties. Tumor-associated macrophages (TAMs) closely resemble the M2-polarized macrophages and are critical modulators of the tumor microenvironment. Clinicopathological studies have suggested that TAM accumulation in tumors correlates with a poor clinical outcome. Consistent with that evidence, experimental and animal studies have supported the notion that TAMs can provide a favorable microenvironment to promote tumor development and progression. In this review article, we present an overview of mechanisms responsible for TAM recruitment and highlight the roles of TAMs in the regulation of tumor angiogenesis, invasion, metastasis, immunosuppression, and chemotherapeutic resistance. Finally, we discuss TAM-targeting therapy as a promising novel strategy for an indirect cancer therapy

Availability note (English)

Available from http://dx.doi.org/10.3390/cancers6031670; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190561

Additional details

Publishing Information

Journal Title
Cancers (Basel)
Journal Volume
6
Journal Issue
3
Journal Page Range
p. 1670-1690
ISSN
2072-6694

INIS

Country of Publication
Switzerland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47006776
Subject category
S60: APPLIED LIFE SCIENCES; S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANGIOGENESIS; BUILDUP; IMMUNOSUPPRESSION; MACROPHAGES; METASTASES; NEOPLASMS; STEM CELLS; THERAPY
Descriptors DEC
ANIMAL CELLS; CONNECTIVE TISSUE CELLS; DISEASES; MEDICINE; PHAGOCYTES; SOMATIC CELLS

Optional Information

Copyright
Copyright (c) 2014 by the authors
Notes
PMCID: PMC4190561; PMID: 25125485; PUBLISHER-ID: cancers-06-01670; OAI: oai:pubmedcentral.nih.gov:4190561; licensee MDPI, Basel, Switzerland.; This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).